Vanguard Global Advisers
UTMD icon

Vanguard Global Advisers’s Utah Medical Products UTMD Stock Holding History

Vanguard Global Advisers’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.3K Hold
1,208
– – ﹤0.01% 2858
2026
Q1 		$74.9K Buy
+1,208
New +$76.1K ﹤0.01% 2846

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Global Advisers's UTMD Position: Q2 2026 in Review

Vanguard Global Advisers held its Utah Medical Products (UTMD) position steady in Q2 2026 at 1,208 shares worth $83.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2858.

Vanguard Global Advisers first reported a position in UTMD in Q1 2026 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

  • Vanguard Global Advisers held 1,208 shares of Utah Medical Products worth $83.3K as of Q2 2026.
  • Vanguard Global Advisers left its Utah Medical Products share count unchanged in Q2 2026.
  • Utah Medical Products made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2858 holding.
  • Vanguard Global Advisers first reported a position in Utah Medical Products in Q1 2026 and has held it in 2 quarters since.
  • 112 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.